BiotechTube

Brivaracetam + Brivaracetam

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epilepsy, Focal

Conditions

Epilepsy, Focal

Trial Timeline

May 1, 2005 → Mar 1, 2006

NCT ID
NCT00175929

About Brivaracetam + Brivaracetam

Brivaracetam + Brivaracetam is a phase 2 stage product being developed by UCB for Epilepsy, Focal. The current trial status is completed. This product is registered under clinical trial identifier NCT00175929. Target conditions include Epilepsy, Focal.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy, Focal were approved

Approved (20) Terminated (6) Active (0)
✅ZonegranEisaiApproved
✅Perampanel + PlaceboEisaiApproved
✅perampanelEisaiApproved
✅Perampanel Oral TabletEisaiApproved
✅PerampanelEisaiApproved
✅zonisamide low dose group + zonisamide high dose groupEisaiApproved
✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT05315947Phase 1Completed
NCT00698581Phase 3Terminated
NCT00699283Phase 3Terminated
NCT00175929Phase 2Completed

Competing Products

20 competing products in Epilepsy, Focal

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
35
LacosamideUCBPhase 3
40
Zonisamide + PlaceboEisaiPhase 3
32
ZonegranEisaiApproved
35
perampanel + perampanelEisaiPhase 1
29
Perampanel + PlaceboEisaiApproved
35
perampanelEisaiApproved
35
E2007 + PlaceboEisaiPhase 2
35
Placebo + RufinamideEisaiPhase 3
40
E2007 (perampanel) + PlaceboEisaiPhase 2
35
Perampanel Oral TabletEisaiApproved
43
perampanelEisaiPhase 3
40
PerampanelEisaiPre-clinical
26
Zonisamide + CarbamazepineEisaiPhase 3
40
PerampanelEisaiApproved
43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
29
PerampanelEisaiPhase 2
35
Zonisamide + PlaceboEisaiPhase 3
40
zonisamide low dose group + zonisamide high dose groupEisaiApproved
43
E2007 + E2007 + PlaceboEisaiPhase 2
35